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ABSTRACT 
 
Background: It has been previously shown that biosimilar infliximab CT-P13 is 
effective and safe in inducing remission in inflammatory bowel diseases (IBD).  
Aim: We report here the one-year outcomes from a prospective nationwide IBD 
cohort. 
Methods: A prospective, nationwide, multicentre, observational cohort was designed 
to examine the efficacy and safety of CT-P13 in the induction and maintenance 
treatment of Crohn’s disease (CD) and ulcerative colitis (UC). Demographic data 
were collected and a harmonized monitoring strategy was applied. Clinical remission, 
response and biochemical response was evaluated at week 14, 30 and 54. Safety data 
was registered. 
Results: 353 consecutive IBD (209 CD and 144 UC) patients were included of which 
229 patients reached the week 54 endpoint at final evaluation. Age at disease onset: 
24/28 years (median, IQR: 19-34/22-39) in CD/UC patients. Forty-nine, 53, 48% and 
86, 81 and 65% of CD patients reached clinical remission and response by week 14, 
30 and 54, respectively. Clinical remission and response rates were 56, 41, 43% and 
74, 66, 50% in UC patients. Clinical efficacy was influenced by previous anti-TNF 
exposure in patients with a drug holiday beyond 1-year. Mean CRP decreased 
significantly in both CD and UC by week 14 and was maintained throughout the 1-
year follow-up (both UC/CD: p<0.001).  31 (8.8%) patients had infusion reactions 
and 32 (9%) patients had infections. ADA positivity rates were significantly higher 
throughout patients with previous anti-TNF exposure, concomitant AZA prevented 
ADA formation in anti-TNF naïve CD patients.  
Conclusions: Results from this prospective nationwide cohort confirm that CT-P13 is 
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 5 
effective and safe in inducing and maintaining long-term remission in both CD and 
UC. Efficacy was influenced by previous anti-TNF exposure, no new safety signals 
were detected.  
 
 
 
 
Key Words: Crohn’s disease, ulcerative colitis, infliximab, biosimilar, antidrug 
antibody, trough level, therapeutic drug monitoring, efficacy, side effects 
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INTRODUCTION 
Biosimilar infliximab (IFX) CT-P13 was approved by the European Medicines 
Agency (EMA) in September 2013 and by the U.S. Food and Drug Administration 
(U.S. FDA) in April 2016 for all indications of the originator product. 1 , 2  The 
extrapolation of the use of biosimilar IFX in inflammatory bowel diseases (IBD) was 
based on the results from two randomized-controlled trials (RCTs) conducted in 
ankylosing spondylitis (AS) and rheumatoid arthritis (RA), which demonstrated 
similarity in pharmacokinetics and clinical efficacy between the biosimilar IFX and 
the originator product.3,4 Since May 2014, the use of biosimilar IFX is mandatory in 
Hungary in all anti-TNF naïve patients and in patients, who were previously treated 
with the originator product with a proven clinical benefit but have been on drug 
holiday for longer than 12 months.  
The efficacy and safety of biosimilar IFX in IBD have been studied in the past 
2 years and real-life cohorts show comparable outcomes as in patients treated with the 
originator IFX.5,6,7,8,9,10,11,12,13,14 As previously reported in the prospective, nationwide, 
multicenter study by our study group published in 2016 including 210 IBD patients, 
high response and remission rates throughout 30 weeks were found in both Crohn’s 
disease (CD) and ulcerative colitis (UC).7 At week 30, 67.2% and 53.4% of CD 
patients showed clinical response or clinical remission, while clinical response or 
remission was demonstrated in 80 % and 68% of UC patients. Early efficacy was 
affected by previous anti-TNF exposure with no new signal in adverse events. 
In the present study, our aim was to evaluate the medium- and long-term 
efficacy, safety and immunogenicity of biosimilar IFX CT-P13 (Inflectra®) in a 
Hungarian consecutive, nationwide cohort of IBD patients treated up-to 54 weeks. 
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MATERIALS AND METHODS 
The present study is a multicenter, nationwide prospective observational study. 
Eligible patients older than 18 years started on biosimilar IFX therapy were 
consecutively enrolled. The inclusion started in May 2014 in 12 IBD centers in 
Hungary.  
A harmonized monitoring strategy was applied in all participating centers, as 
requested by the National Health Fund. Patient demographics, previous and 
concomitant medications were collected and biochemical and clinical assessment was 
performed at start and every 3 months thereafter. Disease location and behavior in CD 
and disease extent in UC were assessed according to the Montreal classification.15 
Patients were either naïve to anti-TNF or had response to previous anti-TNF therapy, 
but were stopped due to non-medical reasons with a drug holiday beyond one-year. A 
more detailed description of the methodology and case ascertainment of the cohort 
was published previously.7 
Patients received intravenous infusions of the biosimilar IFX CT-P13 at a dose 
of 5 mg/kg of body weight at Weeks 0, 2, and 6 and then every eight weeks. Only 
patients with a clinical response at week 14 were eligible for maintenance therapy. 
Clinical response, remission, biochemical response, immunogenicity and safety were 
evaluated at weeks 14, 30 and 54. Patients lost to follow-up or with missing data were 
regarded as non-responders. 
Clinical remission was defined as a Crohn’s Disease Activity Index (CDAI) < 
150 points or no fistula drainage as assessed by the Fistula Drainage Assessment in 
CD, and as a partial Mayo Score (pMayo) of less than 3 points in UC.16,17,18 Clinical 
response was defined as a decrease in CDAI with more than 70 points and/or at least 
50% reduction in the number of draining fistulas in CD, and a decrease in the pMayo 
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score with more than 3 points in UC. Biochemical activity was evaluated by 
measuring total blood count [TBC], serum C-reactive protein [CRP, normal cut-off: 
10 mg/l], and albumin.  
For the measurement of biosimilar IFX trough level (TL) and antidrug 
antibody, a conventional and bridging enzyme-linked immunosorbent assay [ELISA] 
were used [LISA TRACKER, Theradiag, France]. The kit was formally validated for 
the use in patients treated with the biosimilar IFX before commencing on the study. 
All sample measurements were performed at the Department of Laboratory Medicine, 
Semmelweis University, Budapest. The ELISA kit was validated for accuracy and 
reproducibility of therapeutic drug level monitoring [TDM] of the biosimilar IFX 
[Theradiag, France/Hospira, UK]. The detection cut-off value of biosimilar IFX TL 
was 0.1 μg/ml, while 3-7 μg/ml was defined as therapeutic.19,20 For ADA level, the 
standard cut-off value was 10 ng/ml. 
 
Ethical considerations 
Ethical approval was acquired from the National Ethical Committee 929772-
2/2014/EKU [292/2014]). The study was registered at the EMA European Network of 
Centres for Pharmacoepidemiology and Pharmacovigilance [ENCEPP/SDPP/9053]. 
Written informed consent was obtained from all participants. 
 
Statistical analysis 
For the characterization of patients’ demographic data, remission and response rates 
at weeks 14, 30 and 54 and adverse events, descriptive statistics were applied. 
Medians and interquartile ranges were calculated for continuous variables. For the 
comparison of clinical response, remission rates, and antidrug antibody positivity 
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rates between anti-TNF-exposed and naïve patients, Chi2 test or Fisher exact test 
were used. For the comparison of mean CRP levels at week 14, 30 and 54, paired-
sample T test was used. Statistical analysis was performed using SPSS software v. 
20.0 (Chicago, IL); p < 0.05 was considered statistically significant. 
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RESULTS 
A total of 353 consecutive IBD (209 CD and 144 UC) patients were included of 
which 229 patients reached the week 54 endpoint at final assessment. Patient 
characteristics are shown in Table 1. Until week 54, CT-P13 treatment was stopped in 
37 patients due to adverse events, in 11 patients due to primary non-response and in 
27 patients due to loss of response. Two CD and two UC patients were lost to follow-
up (Figure 1). Dose optimization was performed in 17 and 16 of CD/UC patients 
during the follow up period. 
 
Clinical remission and response rates at week 14, 30 and 54 
In CD, 49%, 53%, 48% and 86%, 81% and 65% of the patients reached clinical 
remission and response by week 14, 30 and 54, respectively (Figures 2A, 3A and 4A). 
Stratifying CD patients according to previous anti-TNF exposure, 53.8%, 57% 
and 53.5% of the anti-TNF naïve patients reached clinical remission by weeks 14, 30 
and 54, while 91.1%, 85.9% and 73.3% of the anti-TNF naïve patients reached 
clinical response by week 14, 30 and 54. In patients with a previous anti-TNF 
exposure, clinical remission and response rates were 36.7%, 43.5% and 32.4% and 
67.3%, 67.4% and 44.1% by week 14, 30 and 54 (Figures 2B, 3B and 4B). Clinical 
response rates were significantly different at week 14, 30 and 54 (p<0.01, p=0.005 
and p=0.001), while clinical remission rates were significantly different at week 14 
and 54 (p=0.04, p=0.02) between anti-TNF naïve and anti-TNF exposed CD patients. 
In UC patients, clinical remission and response rates were 56%, 41%, 43% 
and 74%, 66% and 50% of the patients by week 14, 30 and 54 (Figures 2A, 3A and 
4A). 
In anti-TNF naïve UC patients, 59.5%, 45.7% and 47.3% of the patients 
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reached clinical remission by week 14, 30 and 54 and 75%, 71.3% and 51.4% of the 
patients reached clinical response by week 14, 30 and 54. In UC patients with a 
previous anti-TNF exposure, 35.7%, 21.7% and 26.5% of the patients reached clinical 
remission and 67.9%, 43.5% and 42.1% reached clinical response by week 14, 30 and 
54 (Figures 2B, 3B and 4B). Clinical response rates were significantly different at 
week 30 (p=0.01), while clinical remission rates were significantly different at weeks 
14 and 30 (p=0.02, p=0.04) between anti-TNF naïve and previously anti-TNF 
exposed UC patients. 
 
Biochemical response 
In CD patients, the mean CRP level significantly decreased between week 0 and week 
14 from 23.7 mg/L to 9.8 mg/L (p<0.001). Mean CRP levels were 9.4 mg/L and 9.6 
mg/L at weeks 30 and 54 (p<0.001 and p=0.001 compared to baseline). 
Trends were similar in UC. The mean CRP levels were 27.6, 8.7, 12.2 and 
11.7 mg/L at weeks 0, 14, 30 and 54 with a significant decrease by week 14 
(p<0.001), week 30 (p=0.002) and week 54 (p=0.009). 
  
Therapeutic drug level monitoring 
In CD patients, the mean biosimilar IFX TLs at weeks 2, 6, 14, 30 and 54 are 
presented in Table 2. Biosimilar IFX TLs were significantly lower in previously anti-
TNF exposed patients at week 2 (p=0.03), week 14 (p=0.02) and week 30 (p=0.03) 
but not at week 6 (p=0.148) and week 54 (p=0.91) (Table 2).  
In UC patients, the mean biosimilar IFX TLs at weeks 2, 6, 14, 30 and 54 are 
presented also in Table 2. No significant difference was found in biosimilar IFX TLs 
between anti-TNF naïve and previously exposed patients at any time points, with a 
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trend towards higher TLs in the anti-TNF naïve patient group (Table 2).  
Cumulative ADA positivity rates were 9.8% (26/266), 18.6% (58/312), 24.1% 
(70/290) and 33.8% (71/210) at weeks 0, 14, 30 and 54 in all IBD patients. In anti-
TNF naïve IBD patients, cumulative ADA positivity rates were 4.3% (9/213), 12% 
(30/249), 20.9% (48/230) and 28.6% (50/175) at week 0, 14, 30 and 54.  The 
cumulative ADA positivity rates were significantly higher at all time points in anti-
TNF exposed patients 32% (17/53), 34.9% (22/63), 36.6% (22/60) and 46.6% (21/45) 
at week 0, 14, 30 and 54 (p<0.001 for all).  
Cumulative ADA positivity rates in CD and UC patients with and without 
previous anti-TNF exposure are presented in Table 3. In CD, a significant difference 
was found in ADA positivity rates between anti-TNF naïve and previously anti-TNF 
exposed patients at baseline (p<0.001), week 14 (p<0.001), week 30 (p=0.03) and 
week 54 (p=0.03). 
In UC, the difference was significant in baseline ADA positivity rates between 
anti-TNF naïve and previously anti-TNF exposed patients (p<0.001), but this 
difference become non-significant by week 14 and thereafter (week 14: p=0.14; week 
30: p=0.16; week 54: p=0.27).  
Concomitant AZA prevented ADA formation at weeks 14 (6.5% vs. 21.2%, 
p=0.01) 30 (12.7% vs. 29.2%, p=0.02) and 54 (15% vs. 45.2%, p=0.004) in anti-TNF 
naive but not in previously exposed CD patients (week 14: 40% vs. 33.3% p=0.75, 
week 30: 37.5% vs. 38.5%, p=0.95, week 54: 50% vs. 50%, p=1.0). 
In contrast, concomitant AZA did not prevent ADA formation either in anti-
TNF naive (week 14: 19.2% vs. 18.4%, p=0.91, week 30: 24% vs. 22.4%, p=0.85, 
week 54: 29.3% vs. 35%, p=0.58) or in previously exposed UC patients (week 14: 
30% vs. 36.4%, p=0.76, week 30: 40% vs. 36.4%, p=0.86, week 54: 40% vs. 50%, 
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p=0.71). 
Clinical efficacy at week 14 or 30 was not affected by concomitant AZA use 
in either CD or UC patients (CD: week 14 response: 87.2% vs. 81.6%, p=0.28; week 
14 remission: 52% vs. 47.4%, p=0.52; week 30 response: 84.1% vs. 76.8%, p=0.22; 
week 54 response: 69.1% vs. 56.9%, p=0.15; week 54 remission: 50.6% vs. 39.2%, 
p=0.2; UC: week 14 reponse: 73% vs. 74.3%, p=0.85; week 14 remission: 52.7% vs. 
57.1%, p=0.59; week 30 response: 65.6% vs. 66.1%, p=0.95; week 30 remission: 41% 
vs. 41.1%, p=0.99; week 54 response: 48% vs. 51.2%, p=0.76; week 54 remission: 
40% vs. 46.5%, p=0.53). Of note, the clinical remission rates were significantly 
different in CD at week 30 (63.7% vs. 40.6%, p=0.002) and clinical response at week 
30 in previoulsy exposed CD patients (80.8% vs. 44.4%, p=0.01). 
 
Adverse events 
At week 54, the cumulative rate of adverse events was 24%. Infusion reactions 
occurred in 31 (8.8%) patients. Sixteen of 31 patients previously received anti-TNF 
therapy. Infections occurred in 32 (9%) patients with no cases of tuberculosis. One 
patient developed invasive fungal sepsis, resulting in death. No cases of malignancy 
occurred during follow-up of the cohort. Detailed adverse event data are presented in 
Table 4.  
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DISCUSSION 
In the present prospective, multicenter, nationwide study of IBD patients treated with 
the biosimilar IFX, clinical remission and response rates were maintained throughout 
54 weeks and were in line with the previously published data on the originator 
product or CT-P13 biosimilar. In addition, previous anti-TNF exposure affected 
clinical efficacy, while parallel AZA was effective in preventing ADA formation in 
anti-TNF naïve patients.  
The efficacy of maintenance IFX therapy in active CD was demonstrated in the 
ACCENT I trial, where clinical remission rates at week 30 were significantly higher 
in week-2 responder patients receiving IFX 5 mg/kg and 10 mg/kg compared to the 
placebo group (39% and 45% vs. 21%) and the difference between the treatment 
groups remained significant also at week 54.21 In a retrospective Hungarian study, the 
overall response rate was 86.2% (313 out of 363 patients) and the overall remission 
rate was 46% (167 out of 363 patients) at the end of induction therapy with the 
originator IFX in CD patients.22  In addition, in the ACT 1 trial, clinical response and 
remission rates at week 54 were 45.5% and 34.7% in UC patients receiving 5 mg of 
IFX compared to 19.8% and 16.5% in the placebo group.23 
Clinical response, remission rates and safety data24 in the present cohort were in 
line with the above findings and with data presented in real life cohorts treated with 
IFX. In the retrospective study by Jung et al., clinical response and remission were 
achieved by 87.5% and 75% of the anti-TNF naïve CD and 100% and 50% of the 
anti-TNF naïve UC patients at week 54.5 In a Norwegian single-center study, 34 
(79%) CD patients achieved a Harvey-Bradshaw score of ≤4, and 18 (56%) UC 
patients achieved a pMayo score of ≤2 at week 14. In addition, mean serum CRP 
levels significantly decreased from baseline to week 14 both in CD (22.5 vs. 4.9 mg/l; 
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p=0.006) and UC (36.8 vs. 9.6 mg/l; p=0.012).6 High early clinical remission and 
response rates were found in the previous publication from the present cohort in 210 
IBD patients throughout 30 weeks. Clinical response and remission rates at week 14 
were 81 and 54% in CD and 78 and 59% in UC. At week 30, steroid-free clinical 
remission was achieved in 50% of the CD and 56% of the UC patients.7 In a Czech 
study including 52 patients, clinical response (≥70 point-decrease in CDAI score from 
baseline in CD and ≥2-point decrease in partial Mayo score from baseline) and 
remission rates (CDAI<150 in CD and total score on partial Mayo score index ≤2 
points) at week 14 were 50% and 50% in CD and 54.4% and 40.9% in UC.9  
We observed a cumulative adverse event rate of 24% in the present cohort. The 
rate of infusion reactions was 8.8%, of which about half of the patients was 
previously exposed to the originator anti-TNF therapy. The rate of infections (9%) is 
in line with published data on biosimilar or originator IFX. Of note, no cases of 
tuberculosis were identified during follow-up.7 In the study by Keil et al. including 52 
patients, four adverse events occurred during the 14-week follow-up period including 
allergic reaction, phlebothrombosis of the lower extremity, pneumonia and herpes 
labialis.9 Balint et al. investigated the incidence and characteristics of infusion 
reactions in 384 patients from 13 Hungarian and one Czech IBD centers. The rate of 
infusion reactions was 7.2% (21 patients) among Hungarian patients and 13 patients 
of those received previous anti-TNF therapy.25  
In the present study, ADA positivity rates were significantly higher in patients 
with previous exposure of anti-TNF therapy throughout week 54 in CD but this 
difference was non-significant after week 14 in UC. In addition, significantly lower 
early IFX TLs were observed in patients previously exposed to IFX, compared to 
naïve patients. Farkas et al. reported significantly higher IFX TLs in UC patients with 
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mucosal healing or steroid-free mucosal healing compared to patients without 
mucosal healing at week 14.8 In a Norwegian single-center study, four CD and four 
UC patients had an IFX TL of 0 mg/l and three of them received anti-TNF therapy 
previously.  Two of these patients had high (≥80 AU/l), five had medium/high (<80 
AU/l), and one had low ADA levels (<10 AU/l).6 ADA and TL data are awaited from 
the international cross-over study from CD patients treated with originator or 
biosimilar infliximab.26,27 
Parallel AZA was effective in preventing ADA formation in anti-TNF naïve CD 
but not UC patients. Similarly, lower rates of antibodies against IFX were reported by 
Baert et al. in CD patients taking immunosuppressives compared to patients without 
immunosuppressive use during IFX therapy (43% vs. 75%, p<0.01).28 Vermeire at al. 
studied the rate of ATI formation in a multicenter cohort of CD patients receiving 
methotrexate (MTX) and IFX, AZA and IFX or IFX alone. Lower ATI formation was 
observed in CD patients receiving MTX or AZA compared to patients receiving IFX 
alone (46% vs. 73%, p<0.001).29  
Strengths of the present study are the prospective study design and the 
harmonized, standardized follow-up and monitoring strategy in all participating 
centers. A limitation of our study is, that mucosal healing was not systematically 
evaluated. Furthermore, our cohort includes patients with previous drug exposure and 
drug holiday, but not switch.  
In conclusion, in the present multicenter, nationwide cohort including a large 
cohort of IBD patients treated with biosimilar IFX the efficacy, safety and 
immunogenicity of the biosimilar IFX was comparable that of the originator 
compound reported in previous studies. Data on immunogenicity and drug trough 
levels obtained in the present study support the routine use of TDM in patients treated 
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with biosimilar IFX. In addition, parallel AZA was effective in preventing ADA 
formation in anti-TNF naïve patients, while previous anti-TNF exposure affected 
clinical efficacy.  
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TABLES 
 
Table 1. Baseline disease characteristics of patients with inflammatory bowel 
disease on biosimilar IFX therapy 
 
 Crohn’s disease  
(n=209) 
Ulcerative colitis 
(n=144) 
Gender (male/female) 99/110 74/70 
Age at disease onset (median (IQR); 
years) 
24 (19-34) 28 (22-39) 
Disease duration (median 
(IQR); years) 
5 (2-11) 5 (2-11) 
Baseline disease activity (median 
(IQR); points) 
CDAI: 319 (301-352; n=172) 
PDAI: 9 (5-11; n=77) 
Mayo: 9 (7-11; n=136) 
pMayo: 7 (6-9; n=89) 
Disease location (L1/L2/L3/L4/all 
L4; %) 
16.3/31.1/41.1/1.5/8.3 - 
Disease extent (E1/E2/E3; %) - 9.7/34.1/56.2 
Disease behavior (B1/B2/B3; %) 56.5/21.0/22.5 - 
Perianal disease (%) 39.2 - 
Previous surgery (%) 21.5 - 
Previous anti-TNF therapy (%) 
  IFX 
  Adalimumab 
  IFX + adalimumab 
23.4 (n=49) 
18.2  (n=38) 
4.2  (n=9) 
1     (n=2) 
19.4 (n=28) 
12.5 (n=18) 
6.2 (n=9) 
0.7 (n=1) 
Concomitant steroid therapy (%) 42.6 64.6 
Concomitant AZA therapy (%) 60.3 51.4 
 
 
(IQR, interquartile range; CD, Crohn’s disease; UC, ulcerative colitis; IFX, 
infliximab; 5ASA, 5-aminosalicylates; AZA, azathioprine; TNF, tumor necrosis 
factor; ADA, anti-drug antibody; PDAI, Perianal Disease Activity Index; CDAI, 
Crohn’s Disease Activity Index) 
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Table 2. Mean trough levels in patients with inflammatory bowel disease on 
biosimilar IFX therapy 
 
 
week 2 week 6 week 14 week 30 week 54 
CD 
Mean biosimilar 
IFX TLs 
18.9 μg/mL 
(n=85) 
17.3 μg/mL 
(n=74) 
6.1 μg/mL 
(n=136) 
4.3 μg/mL 
(n=119) 
5.3 μg/mL 
(n=53) 
Without previous 
anti-TNF 
20.4 μg/mL* 16.5 μg/mL 6.5 μg/mL* 4.6 μg/mL* 5.4 μg/mL 
With previous 
anti-TNF 
11.7 μg/mL* 10.7 μg/mL 3.7 μg/mL* 2.1 μg/mL* 5.0 μg/mL 
UC 
Mean biosimilar 
IFX TLs 
19.0 μg/mL 
(n=67) 
11.8 μg/mL 
(n=50) 
4.9 μg/mL 
(n=97) 
3.9 μg/mL 
(n=63) 
4.5 μg/mL 
(n=39) 
Without previous 
anti-TNF 
20.6 μg/mL 12.9 μg/mL 4.9 μg/mL 4.0 μg/mL 4.9 μg/mL 
With previous 
anti-TNF 
9.9 μg/mL 5.7 μg/mL 4.8 μg/mL 3.3 μg/mL 1.9 μg/mL 
* Mean biosimilar IFX TLs differed significantly between anti-TNF naïve and previously 
anti-TNF exposed patients at week 2 (p=0.03), at week 14 (p=0.02) and at week 30 (p=0.03) 
in CD 
 
 
(CD, Crohn’s disease; UC, ulcerative colitis; TNF, tumour necrosis factor; TL, trough 
level) 
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Table 3. Cumulative antidrug antibody positivity in patients with inflammatory 
bowel disease on biosimilar IFX therapy 
 
 ADA 
positivity at 
baseline 
ADA 
positivity at 
week 14 
ADA 
positivity at 
week 30 
ADA 
positivity at 
week 54 
CD 15/169 
(8.9%) 
32/190 
(16.8%) 
39/170 
(22.9%) 
38/124 
(30.6%) 
Without 
previous anti-
TNF 
5/134 
(3.7%)* 
17/148 
(11.5%)* 
25/131 
(19.1%)* 
24/94 
(25.5%)* 
With previous 
anti-TNF 
10/35 
(28.6%)* 
15/42 
(35.7%)* 
14/39 
(35.9%)* 
14/30 
(46.7%)* 
UC 11/97 
(11.3%) 
26/122 
(21.3%) 
31/120 
(25.8%) 
33/96 
(34.4%) 
Without 
previous anti-
TNF* 
4/79 
(5.1%)* 
13/101 
(18.8%) 
23/99 
(23.2%) 
26/81 
(32.1%) 
With previous 
anti-TNF 
7/18 
(38.9%)* 
7/21 
(33.3%) 
8/21 
(38.1%) 
7/15 
(46.7%) 
*ADA positivity rates differed significantly between anti-TNF naïve and previously anti-TNF 
exposed patients at baseline (p<0.001), at week 14 (p<0.001), at week 30 (p=0.03) and at 
week 54 (p=0.03) in CD and at baseline (p<0.001) in UC 
 
(CD, Crohn’s disease; UC, ulcerative colitis; TNF, tumour necrosis factor; ADA, anti-
drug antibody) 
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Table 4. Adverse events in patients with inflammatory bowel disease on 
biosimilar IFX therapy 
 
Adverse event Patients (%) 
Mortality 1 (0.3%) 
Infections 
 Upper respiratory tract infection  
 Gastroenteritis 
 Viral infections (influenza, herpes, varicella) 
 C. difficile colitis 
 Invasive fungal infection 
 Pneumonia 
 Urinary tract infection 
 Tuberculosis 
 
9 (2.5%) 
10 (2.8%) 
7 (2%) 
3 (0.8%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
0 (0%) 
Allergy 
 Infusion reaction 
 Anaphylaxis 
 
31 (8.8%) 
1 (0.3%) 
Others 
 Arthralgia 
 Delayed hypersensitivity 
 Malignancy 
 
11 (3.1%) 
10 (2.8%) 
0 (0%) 
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FIGURES 
 
 
Figure 1. Patients and follow-up 
(PNR: primary non-response, LOR: loss of response, AE: adverse event; 2 CD 
patients and 2 UC patients were lost to follow-up.) 
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Figure 2A. Clinical response and remission rates at week 14 in patients with 
inflammatory bowel disease treated with the biosimilar IFX 
 
 
 
 
 
 
(CD, Crohn’s disease; UC, ulcerative colitis) 
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Figure 2B. Clinical response and remission rates at week 14 in patients with 
inflammatory bowel disease treated with the biosimilar IFX stratified by 
previous anti-TNF exposure; *p<0.05 
 
 
 
 
 
 
 
 
(CD, Crohn’s disease; UC, ulcerative colitis) 
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Figure 3A. Clinical response and remission rates at week 30 in patients with 
inflammatory bowel disease treated with the biosimilar IFX 
 
 
 
 
 
(CD, Crohn’s disease; UC, ulcerative colitis) 
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Figure 3B. Clinical response and remission rates at week 30 in patients with 
inflammatory bowel disease treated with the biosimilar IFX stratified by 
previous anti-TNF exposure; *p<0.05 
 
 
 
 
 
 
 
(CD, Crohn’s disease; UC, ulcerative colitis) 
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Figure 4A. Clinical response and remission rates at week 54 in patients with 
inflammatory bowel disease treated with the biosimilar IFX 
 
 
 
 
 
 
 
 
(CD, Crohn’s disease; UC, ulcerative colitis) 
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Figure 4B. Clinical response and remission rates at week 54 in patients with 
inflammatory bowel disease treated with the biosimilar IFX stratified by 
previous anti-TNF exposure; *p<0.05 
 
 
 
 
 
 
 
(CD, Crohn’s disease; UC, ulcerative colitis) 
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Table and figure legends: 
 
 
Table 1. Baseline disease characteristics of patients with inflammatory bowel disease 
on biosimilar IFX therapy 
 
Table 2. Mean trough levels in patients with inflammatory bowel disease on 
biosimilar IFX therapy 
 
Table 3. Cumulative antidrug antibody positivity in patients with inflammatory bowel 
disease on biosimilar IFX therapy 
 
Table 4. Adverse events in patients with inflammatory bowel disease on biosimilar 
IFX therapy 
 
Figure 1. Patients and follow-up 
 
Figure 2A. Clinical response and remission rates at week 14 in patients with 
inflammatory bowel disease treated with the biosimilar IFX 
 
Figure 2B. Clinical response and remission rates at week 14 in patients with 
inflammatory bowel disease treated with the biosimilar IFX stratified by previous 
anti-TNF exposure; *p<0.05 
 
Figure 3A. Clinical response and remission rates at week 30 in patients with 
inflammatory bowel disease treated with the biosimilar IFX 
 
Figure 3B. Clinical response and remission rates at week 30 in patients with 
inflammatory bowel disease treated with the biosimilar IFX stratified by previous 
anti-TNF exposure; *p<0.05 
 
Figure 4A. Clinical response and remission rates at week 54 in patients with 
inflammatory bowel disease treated with the biosimilar IFX 
 
Figure 4B. Clinical response and remission rates at week 54 in patients with 
inflammatory bowel disease treated with the biosimilar IFX stratified by previous 
anti-TNF exposure; *p<0.05 
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STROBE Statement—Checklist of items that should be included in reports of 
cohort studies  
 
 
 Item 
No Recommendation 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title 
or the abstract [on the Title page 1 and page 3] 
(b) Provide in the abstract an informative and balanced summary of 
what was done and what was found [pages 3-4] 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported [pages 5-6] 
Objectives 3 State specific objectives, including any prespecified hypotheses 
[page 6] 
Methods 
Study design 4 Present key elements of study design early in the paper [pages 7-8] 
Setting 5 Describe the setting, locations, and relevant dates, including periods 
of recruitment, exposure, follow-up, and data collection [pages 7-8] 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up [pages 7-8] 
(b) For matched studies, give matching criteria and number of 
exposed and unexposed [NA] 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable [pages 7-8] 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group [pages 7-8] 
Bias 9 Describe any efforts to address potential sources of bias [page 7] 
Study size 10 Explain how the study size was arrived at – patients with no 
available week 14 outcomes were excluded from the analysis 
[page 7] 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why [pages 7-
8] anti-TNF naïve patients and patients previously exposed to 
anti-TNF were analysed also separately 
Statistical methods 12 (a) Describe all statistical methods, including those used to control 
for confounding [pages 8-9] 
(b) Describe any methods used to examine subgroups and 
interactions [pages 8-9] 
(c) Explain how missing data were addressed – an ITT analysis was 
applied, patients loss-to-follow up or with missing data were 
regarded as non-responders [page 7] 
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(d) If applicable, explain how loss to follow-up was addressed - an 
ITT analysis was applied, patients loss-to-follow up or with 
missing data were regarded as non-responders [page 7] 
(e) Describe any sensitivity analyses [NA] 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and analysed 
[Figures 1-3] 
(b) Give reasons for non-participation at each stage – [page 7] 
(c) Consider use of a flow diagram – [page 22] 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders [Table 1] 
(b) Indicate number of participants with missing data for each 
variable of interest shown as appropriate 
(c) Summarise follow-up time (eg, average and total amount) [pages 
7 and 10] 
Outcome data 15* Report numbers of outcome events or summary measures over time 
[pages 10-14] 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make 
clear which confounders were adjusted for and why they were 
included [pages 10-14] multivariate analysis was used as 
appropriate 
(b) Report category boundaries when continuous variables were 
categorized [pages 10-14] 
(c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period [NA] 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses [pages 10-14] 
Discussion 
Key results 18 Summarise key results with reference to study objectives [pages 15-
17] 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and magnitude 
of any potential bias [pages 17-18] 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from similar 
studies, and other relevant evidence pages 15-18] 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
[page 18] 
Other information 
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Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 
article is based [page 19] 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and 
Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at 
http://www.strobe-statement.org. 
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 Crohn’s disease  
(n=209) 
Ulcerative colitis 
(n=144) 
Gender (male/female) 99/110 74/70 
Age at disease onset (median (IQR); 
years) 
24 (19-34) 28 (22-39) 
Disease duration (median 
(IQR); years) 
5 (2-11) 5 (2-11) 
Baseline disease activity (median 
(IQR); points) 
CDAI: 319 (301-352; n=172) 
PDAI: 9 (5-11; n=77) 
Mayo: 9 (7-11; n=136) 
pMayo: 7 (6-9; n=89) 
Disease location (L1/L2/L3/L4/all 
L4; %) 
16.3/31.1/41.1/1.5/8.3 - 
Disease extent (E1/E2/E3; %) - 9.7/34.1/56.2 
Disease behavior (B1/B2/B3; %) 56.5/21.0/22.5 - 
Perianal disease (%) 39.2 - 
Previous surgery (%) 21.5 - 
Previous anti-TNF therapy (%) 
  IFX 
  Adalimumab 
  IFX + adalimumab 
23.4 (n=49) 
18.2  (n=38) 
4.2  (n=9) 
1     (n=2) 
19.4 (n=28) 
12.5 (n=18) 
6.2 (n=9) 
0.7 (n=1) 
Concomitant steroid therapy (%) 42.6 64.6 
Concomitant AZA therapy (%) 60.3 51.4 
 
Table1_revised
 week 2 week 6 week 14 week 30 week 54 
CD 
Mean biosimilar 
IFX TLs 
18.9 μg/mL 
(n=85) 
17.3 μg/mL 
(n=74) 
6.1 μg/mL 
(n=136) 
4.3 μg/mL 
(n=119) 
5.3 μg/mL 
(n=53) 
Without previous 
anti-TNF 
20.4 μg/mL* 16.5 μg/mL 6.5 μg/mL* 4.6 μg/mL* 5.4 μg/mL 
With previous 
anti-TNF 
11.7 μg/mL* 10.7 μg/mL 3.7 μg/mL* 2.1 μg/mL* 5.0 μg/mL 
UC 
Mean biosimilar 
IFX TLs 
19.0 μg/mL 
(n=67) 
11.8 μg/mL 
(n=50) 
4.9 μg/mL 
(n=97) 
3.9 μg/mL 
(n=63) 
4.5 μg/mL 
(n=39) 
Without previous 
anti-TNF 
20.6 μg/mL 12.9 μg/mL 4.9 μg/mL 4.0 μg/mL 4.9 μg/mL 
With previous 
anti-TNF 
9.9 μg/mL 5.7 μg/mL 4.8 μg/mL 3.3 μg/mL 1.9 μg/mL 
 
Table2
 ADA positivity 
at baseline 
ADA positivity 
at week 14 
ADA positivity 
at week 30 
ADA positivity 
at week 54 
CD 15/169 
(8.9%) 
32/190 
(16.8%) 
39/170 
(22.9%) 
38/124 
(30.6%) 
Without 
previous anti-
TNF 
5/134 
(3.7%)* 
17/148 
(11.5%)* 
25/131 
(19.1%)* 
24/94 
(25.5%)* 
With previous 
anti-TNF 
10/35 
(28.6%)* 
15/42 
(35.7%)* 
14/39 
(35.9%)* 
14/30 
(46.7%)* 
UC 11/97 
(11.3%) 
26/122 
(21.3%) 
31/120  
(25.8%) 
33/96 
(34.4%) 
Without 
previous anti-
TNF* 
4/79 
(5.1%)* 
13/101 
(18.8%) 
23/99 
(23.2%) 
26/81 
(32.1%) 
With previous 
anti-TNF 
7/18 
(38.9%)* 
7/21 
(33.3%) 
8/21 
(38.1%) 
7/15 
(46.7%) 
 
Table3
Adverse event Patients (%) 
Mortality 1 (0.3%) 
Infections 
 Upper respiratory tract infection  
 Gastroenteritis 
 Viral infections (influenza, herpes, varicella) 
 C. difficile colitis 
 Invasive fungal infection 
 Pneumonia 
 Urinary tract infection 
 Tuberculosis 
 
9 (2.5%) 
10 (2.8%) 
7 (2%) 
3 (0.8%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
0 (0%) 
Allergy 
 Infusion reaction 
 Anaphylaxis 
 
31 (8.8%) 
1 (0.3%) 
Others 
 Arthralgia 
 Delayed hypersensitivity 
 Malignancy 
 
11 (3.1%) 
10 (2.8%) 
0 (0%) 
 
Table4
Image1 Click here to download Image figure1_biosimilar_1y.tif 
Image2a Click here to download Image figure2a_biosimilar_1y.tif 
Image2b Click here to download Image figure2b_biosimilar_1y.tif 
Image3a Click here to download Image figure3a_biosimilar_1y.tif 
Image3b Click here to download Image figure3b_biosimilar_1y.tif 
Image4a Click here to download Image figure4a_biosimilar_1y.tif 
Image4b Click here to download Image figure4b_biosimilar_1y.tif 
